Seroatlas · Human Serome Atlas

PSMC3

26S proteasome regulatory subunit 6A

Also known as: PRS6A_HUMAN, RPT5, TBP-1, TBP1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P17980
Gene
PSMC3
Ensembl
ENSG00000165916
Chromosome
11
Canonical length
439 aa
Protein class
Disease related genes, Plasma proteins, Predicted intracellular proteins
Subcellular location
Nucleoplasm,Nuclear bodies,Cytosol

OverviewNCBI Gene

The 26S proteasome is a multicatalytic proteinase complex with a highly ordered structure composed of 2 complexes, a 20S core and a 19S regulator. The 20S core is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. The 19S regulator is composed of a base, which contains 6 ATPase subunits and 2 non-ATPase subunits, and a lid, which contains up to 10 non-ATPase subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes one of the ATPase subunits, a member of the triple-A family of ATPases that have chaperone-like activity. This subunit may compete with PSMC2 for binding to the HIV tat protein to regulate the interaction between the viral protein and the transcription complex. A pseudogene has been identified on chromosome 9. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

439 residues, UniProt reviewed canonical sequence.

>P17980|PSMC3
     1  MNLLPNIESP VTRQEKMATV WDEAEQDGIG EEVLKMSTEE IIQRTRLLDS EIKIMKSEVL
    61  RVTHELQAMK DKIKENSEKI KVNKTLPYLV SNVIELLDVD PNDQEEDGAN IDLDSQRKGK
   121  CAVIKTSTRQ TYFLPVIGLV DAEKLKPGDL VGVNKDSYLI LETLPTEYDS RVKAMEVDER
   181  PTEQYSDIGG LDKQIQELVE AIVLPMNHKE KFENLGIQPP KGVLMYGPPG TGKTLLARAC
   241  AAQTKATFLK LAGPQLVQMF IGDGAKLVRD AFALAKEKAP SIIFIDELDA IGTKRFDSEK
   301  AGDREVQRTM LELLNQLDGF QPNTQVKVIA ATNRVDILDP ALLRSGRLDR KIEFPMPNEE
   361  ARARIMQIHS RKMNVSPDVN YEELARCTDD FNGAQCKAVC VEAGMIALRR GATELTHEDY
   421  MEGILEVQAK KKANLQYYA

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PSMC3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.35
Highest tissue expression
286 nTPM

Expression across tissuesHPA

Tissue

  • skeletal muscle: 286 nTPM
  • heart muscle: 164 nTPM
  • tongue: 152 nTPM
  • basal ganglia: 151 nTPM
  • choroid plexus: 144 nTPM
  • cerebral cortex: 130 nTPM

Single-cell type

  • syncytiotrophoblasts: 440 nCPM
  • late primary spermatocytes: 330 nCPM
  • late spermatids: 322 nCPM
  • cytotrophoblasts: 315 nCPM
  • extravillous trophoblasts: 311 nCPM
  • migrating cytotrophoblasts: 283 nCPM

Immune cell

  • total PBMC: 255 nTPM
  • non-classical monocyte: 213 nTPM
  • intermediate monocyte: 195 nTPM
  • T-reg: 191 nTPM
  • NK-cell: 174 nTPM
  • gdT-cell: 161 nTPM

Brain region

  • basal ganglia: 97 nTPM
  • thalamus: 97 nTPM
  • midbrain: 95 nTPM
  • pons: 87 nTPM
  • cerebral cortex: 82 nTPM
  • medulla oblongata: 81 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about PSMC3.

Disease | AllUniProt

Conditions PSMC3 is implicated in, by any mechanism.

  • Deafness, cataract, impaired intellectual development, and polyneuropathy (DCIDP) MIM:619354

Disease | GeneticClinVar

11 pathogenic / likely-pathogenic of 76 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.34
gnomAD pLI
0.95
gnomAD missense Z
3.87
DepMap mean gene effect
-1.72
DepMap dependency class
pan

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of PSMC3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PSMC3 as an antibody target. Whether an autoantibody or antibody against PSMC3 could matter depends on whether native PSMC3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PSMC3 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label PSMC3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/PSMC3. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...